

## **Novel Therapeutics Delivery FY25 Application**

| Applicant Name (Organization) (required)              |
|---|
| Select v  |
| This will automatically be blinded to reviewers.      |
| Non-Profit Principal Investigator (required)          |
|   |
| First Name Last Name                                  |
| This will automatically be blinded to reviewers.      |
| Title of Non-Profit Principal Investigator (required) |
|   |
| This will automatically be blinded to reviewers.      |
| Email of Non-Profit Principal Investigator (required) |
| email@example.com                                     |
| This will automatically be blinded to reviewers.      |
| Phone of Non-Profit Principal Investigator (required) |
| <b>■</b> ×  |
| This will automatically be blinded to reviewers.      |
|   |
| Authorized Representative (required)                  |
|   |
| This will automatically be blinded to reviewers.      |
| Title of Authorized Representative (required)         |
|   |

Email of Authorized Representative (required)

This will automatically be blinded to reviewers.

| emaii    | @example.com         |                          |                   |              |                  |                          |                    |
|----------|----------------------|--------------------------|-------------------|--------------|------------------|--------------------------|--------------------|
| This wi  | ill automatically be | blinded to reviewer      | S.                |              |                  |                          |                    |
| Addr     | ess of Non-Pro       | <b>fit Address</b> (requ | uired)            |              |                  |                          |                    |
| This wi  | ill automatically be | blinded to reviewer      | S.                |              |                  |                          |                    |
| City/    | Γown of Non-P        | rofit Entity (requi      | red)              |              |                  |                          |                    |
| Selec    | ct                   |                          |                   |              |                  |                          | ~                  |
| This wi  | ill automatically be | blinded to reviewer      | S.                |              |                  |                          |                    |
| Zip C    | ode of Non-Pro       | ofit Entity (require     | ed)               |              |                  |                          |                    |
| Selec    | ct                   |                          |                   |              |                  |                          | ~                  |
| This wi  | ill automatically be | blinded to reviewer      | S.                |              |                  |                          |                    |
| Name     | e of Press Cont      | tact (required)          |                   |              |                  |                          |                    |
| This wi  | ill automatically be | blinded to reviewer      | S.                |              |                  |                          |                    |
| Email    | Address of Pr        | ess Contact (req         | juired)           |              |                  |                          |                    |
| email    | @example.com         |                          |                   |              |                  |                          |                    |
| This wi  | ill automatically be | blinded to reviewer      | S.                |              |                  |                          |                    |
| Press    | Contact Telep        | phone (required)         |                   |              |                  |                          |                    |
| <b>-</b> |                      |                          |                   |              |                  |                          |                    |
| This wi  | ill automatically be | blinded to reviewer      | S.                |              |                  |                          |                    |
|          |                      |                          |                   |              |                  |                          |                    |
| Proje    | ct Team Memb         | <b>Ders</b> (required)   |                   |              |                  |                          |                    |
|          |                      |                          |                   |              |                  |                          |                    |
|          | А                    | В                        | С                 | D            | E                | F                        |                    |
| 1        |                      | Organization<br>Name     | Entity Type (For- | Contact Name | Title of Contact | Organization<br>Location | Contact<br>Address |

Profit)

|                | Α   | В                | С               | D               | Е              | F               | (             |  |
|----------------|---|------------------|-----------------|-----------------|----------------|-----------------|---------------|--|
| 2              | 1   |                  |                 |                 |                |                 |               |  |
| 3              | 2   |                  |                 |                 |                |                 |               |  |
| 4              | 3   |                  |                 |                 |                |                 |               |  |
| 5              | 4   |                  |                 |                 |                |                 | -             |  |
| 6              | 5   |                  |                 |                 |                |                 |               |  |
| 7              |   |                  |                 |                 |                |                 |               |  |
| /              | 6   |                  |                 |                 |                |                 |               |  |
| In an eidentit | n an effort to review all applications, based solely on the merits of the proposal and qualifications of the team, the MLSC will blind the dentities of team members to reviewers during the review process.  Non-Profit PI Lead Name (required)  This will automatically be blinded to reviewers.  Non-Profit PI Title and Department (required) |                  |                 |                 |                |                 |               |  |
|                |   | •                |                 |                 |                |                 |               |  |
| Non-           | Profit PI Institut  | ion (required)   |                 |                 |                |                 |               |  |
|                |   |                  |                 |                 |                |                 |               |  |
| Pleas          | se describe the   | PI's relevant ex | rperience, with | out identifying | him/her by nar | ne or gender. ( | required)     |  |
|                |   |                  |                 |                 |                |                 |               |  |
|                |   |                  |                 |                 |                |                 |               |  |
|                |   |                  |                 |                 |                | Lim             | it: 500 words |  |

Please don't use PI's name or gendered pronouns (he/him/his or she/her/hers). Ex. The PI has 10 years of experience administering and managing projects, several of which have included small clinical trials. The PI is the research group leader with expertise in the areas of XYZ...

## Company 1: Lead Scientist Name (required)

| Last Name (required)  |                       |
|---|-----------------------|
|   |                       |
| This field will be blinded to reviewers.  |                       |
| Company 1: Title and Department (required)  |                       |
|   |                       |
| Company 1: Company Name (required)  |                       |
|   |                       |
| Company 1: Please describe the company lead's relevant experience without ider name or gender. (required)   | ntifying him/her by   |
|   |                       |
|   | Limit: 150 words      |
| Ex. The X at the company has more than 10 years of medical device experience, where they developed r to deliver compounds through subcutaneous infusion. The lead has held previous roles as X, responsible |                       |
| Company 1: Please describe the company's role in the project proposal, without in the team by name. (required)  | dentifying members of |
| the team by hame. (required)  |                       |
|   |                       |
|   |                       |
|   | Limit: 150 words      |
| Do you have another industry partner? (required)  |                       |
| Yes   |                       |
| ○ No  |                       |
| Please upload a job description for the new postdoctoral scientist to be hired, wh qualifications of the new candidate you will be seeking in addition to their respon                                      |                       |
| <br>  |                       |
| Choose File   |                       |

Acceptable file types: .pdf

Note: Uploaded document must be in .PDF file format.

| 1. Pr | oposal Title (required)         |        |   |         |                                    |        |                              |
|-------|---------------------------------|--------|---|---------|------------------------------------|--------|------------------------------|
| Wha   | nt disease(s) does thi          | is pro | ject primarily study?                     | Pleas   | e choose up to three               | optic  | <b>DNS.</b> (required)       |
|       | Agriculture                     |        | Autoimune Disorders                       |         | Cancer - Breast                    |        | Cancer - Others              |
|       | Cancer - Ovarian                |        | Cardiology/<br>Cardiovascular<br>Research |         | Chronic<br>Illness/Disease         |        | Endocrinology                |
|       | Environmental Health            |        | Gastrointestinal (GI)                     |         | Geriatrics &<br>Gerontology        |        | Hematology                   |
|       | Immunology/Inflammat            |        | Infectious Diseases                       |         | Liver                              |        | Maternal/Infant Health       |
|       | Metabolic Diseases              |        | Microbiome                                |         | Neuroscience                       |        | Nutritional Science          |
|       | Oral Health                     |        | Orthopedic Research                       |         | Pediatric Research                 |        | Psychiatry/ Mental<br>Health |
|       | Public Health/<br>Epidemiology  |        | Rare Diseases                             |         | Regenerative<br>Medicine           |        | Reproductive Health          |
|       | Toxicology                      |        | Women's Health/<br>Gender Studies         |         | Other                              |        | N/A                          |
|       | at modality/modalitie<br>uired) | s doe  | es your project prima                     | rily en | nploy? Please choos                | e up t | o three options.             |
|       | Cell & Gene Therapy             |        | Clinical Trials                           |         | Data Science                       |        | Diagnostics                  |
|       | Digital Health                  |        | Drug Delivery                             |         | Drug Discovery & Development       |        | Imaging                      |
|       | Medical Device                  |        | mRNA/siRNA/ RNA<br>Research               |         | Personalized/Precision<br>Medicine |        | Phototherapy                 |
|       | Radiation Therapy               |        | Robotics                                  |         | Vaccines                           |        | Other                        |
|       | N/A                             |        |   |         |                                    |        |                              |
| Wha   | at are tools and techi          | nique  | s used in your projed                     | ct? Ple | ease choose up to thi              | ee op  | otions. (required)           |

AI/ML/Deep Learning

Antibody

Automation

Proposal to MLSC

3D printing

|        | Biomanufacturing                 |         | Biomarker<br>Identification        |        | Biomaterials/ Material<br>Sciences |                 | Biosensor                                 |
|--------|----------------------------------|---------|------------------------------------|--------|------------------------------------|-----------------|---|
|        | Contract Work-<br>CRO/CDMO/CMO   |         | Crystallography/Peptid e synthesis |        | CT/MRI                             |                 | Data Optimization                         |
|        | EEG&ECG                          |         | Electronic Medical<br>Record (EMR) |        | Engineered Microbes                |                 | FACS/ Flow Cytometry                      |
|        | Genome Editing                   |         | Genomics                           |        | In Vitro cultures                  |                 | In Vivo animal models                     |
|        | Liquid<br>Chromatography         |         | Mass Spectroscopy                  |        | Metabolomics                       |                 | Microscopy                                |
|        | Nanotechnology                   |         | Next-generation<br>Sequencing      |        | NMR/MRS                            |                 | Organoid/ Organ-on-a-<br>chip             |
|        | Pasteurization/<br>Sterilization |         | Patient Avatars                    |        | Proteomics                         |                 | Small Molecule                            |
|        | Software & Algorithms            |         | Transcriptomics                    |        | Ultrasound                         |                 | Viral Vector                              |
|        | Other                            |         | N/A                                |        |                                    |                 |   |
| 3. D   | escribe the clinical/s           | scienti | fic need or problem                | the p  | roject seeks to addre              | <b>PSS.</b> (re | Limit: 75 words equired) Limit: 150 words |
| 4. D   | escribe the current s            | solutio | on. (required)                     |        |                                    |                 |   |
|        |                                  |         |                                    |        |                                    |                 |   |
|        |                                  |         |                                    |        |                                    |                 | Limit: 150 words                          |
|        | escribe the potentia             | l impa  | act and the important              | ce the | e project will have in             | movir           | ng this field forward.                    |
| (1.54) |                                  |         |                                    |        |                                    |                 |   |
|        |                                  |         |                                    |        |                                    |                 |   |

Limit: 250 words

| 6. What are the detailed activities (including experimental design, if you already have the samples on hand or anticipated time to acquire, and type of analysis) you propose to meet the milestones outlined with the MLSC funds? (required)    |
|--|
|  |
|  |
|  |
| Limit: 300 word  |
| 7. What is the gender distribution between animals/cell lines to be studied and how will gender  |
| differences be reported? If gender will not be studied in equal numbers, please explain why. (required)  |
|  |
|  |
|  |
| Limit: 50 word   |
| 8. What is the distribution of racial, geographic, and any other identifiable social determinants of healtl and how will differences be reported? Please list which factors will be studied. If none are studied, please explain why. (required) |
|  |
|  |
|  |
| Limit: 50 word   |
| 9. What is your competitive advantage over other similar approaches in this field? (required)  |
|  |
|  |
|  |
| Limit: 100 word  |
| 10. What is the current intellectual property status (including foundational IP)? Is IP generation under this project expected? (required)   |
|  |
|  |
|  |
| Limit: 75 word   |
| 11. Does the requested capital equipment already exist at your institution or others in the state? If so,  |
| please describe the value in purchasing additional infrastructure. (required)  |
|  |
|  |

| available to the public. Please describe                                 | al equipment/data purchased using MLSC funds be made<br>be your plans for promoting and allowing access to outside<br>the business model of the facility (if applicable). (required) |
|--|--|
|  |  |
|  | Limit: 250 words   |
| institution/industry partner(s). The letter                              | B max) from academic scientists external to your<br>er should include a brief (3 sentence) description describing a<br>sipment and/or data set generated under the award. (required) |
|  | Choose File  |
| Upload a file. No files have been attached yet.                          |  |
| Acceptable file types: .pdf  |  |
| •  | B max) from industry scientists external to your institution/industry brief (3 sentence) description describing a project that would use generated under the award. (required)       |
|  | Choose File  |
| Upload a file. No files have been attached yet.                          |  |
| Acceptable file types: .pdf  |  |
| 15. What are the key challenges to suc plan to overcome them? (required) | ccessful translation of the outcomes/technology and how do you   |
|  |  |
|  | Limit: 200 words   |
|  | sed project in Massachusetts (in the context of local business or ng, local prototyping, patients, jobs etc.) (required)   |
|  |  |
|  |  |

Limit: 200 words

|   |   | ew postdoctoral sc | ientist(s), and what a  | dditional skillsets |
|---|---|--------------------|-------------------------|---------------------|
|   |   |                    |                         |                     |
| Financial Considerations and Project Timeline  18. Total amount requested from MLSC (required)  \$ USD  19. Total Committed from Industry Partner(s) (required)  \$ USD  20. Total Committed from Non-Profit Applicant(s) (required)  \$ USD  21. Typical grant requests for this program are up to \$750,000. If you are requesting more than \$750,000, please describe the compelling circumstances and provide sufficient information to justify this special request. The Center reserves the right to adjust the requested amount. (required) |   |                    |                         |                     |
| Financial Considerations and Project Timeline  18. Total amount requested from MLSC (required)  \$  |   |                    |                         |                     |
| 18. T   | otal amount requested from MLSC (require    | red)               |                         |                     |
| \$  | USD   |                    |                         |                     |
|   |   | (required)         |                         |                     |
| \$  | USD   |                    |                         |                     |
| 20.   | Total Committed from Non-Profit Applica     | ant(s) (required)  |                         |                     |
| \$  | USD   |                    |                         |                     |
| \$750   | 0,000, please describe the compelling ci    | ircumstances and p | provide sufficient info | ormation to justify |
|   |   |                    |                         |                     |
| Financial Considerations and Project Timeline  18. Total amount requested from MLSC (required)  \$  |   |                    |                         |                     |
|   |   |                    | SC Budget to show t     | the detailed        |
|   |   |                    |                         | e p                 |
|   | А   | В                  | С                       | D                   |
| 1   | MLSC Expenses for Project                   |                    |                         |                     |
| 2   | Supplies/Reagents, Renovation/Construction, |                    |                         |                     |

|   | А   | В           | С | D |
|---|---|-------------|---|---|
| 4 | Total Contribution MLSC   | 0           |   |   |
| 5 | FY26 (7/1/25 – 6/30/26)   | 0           |   |   |
| 6 | FY27 (7/1/26 – 6/30/27)   | 0           |   |   |
| 7 | FY28 (7/1/27 – 6/30/28)   | 0           |   |   |
| 8 |   |             |   |   |
|   | or the MLSC Budget, please include verse only include the page that shows the | •           |   |   |
|   |   | Choose File |   |   |

Upload a file. No files have been attached yet.

Acceptable file types: .pdf

DO NOT MENTION THE PI BY NAME OR GENDER IN ANY UPLOADS.

24. Breakdown of Academic Non-Profit Expenditures: Please complete the Academic Budget to show the detailed breakdown of expenditures for funds to be contributed by the Academic Partner(s). For this application, contributions includes funds committed or dollars leveraged. This can include contributions from for-profit institutions and non-profit/federal entities.

|   |  |   |   |   | 4 |
|---|--|---|---|---|---|
|   | А  | В | С | D | E |
| 1 | Academic Non-Profit Expenses for<br>Project  |   |   |   |   |
| 2 | Category Options: Equipment, Supplies/Reagents, Renovation/Construction, Salaries, Indirects, Facility Costs |   |   |   |   |
| 3 |  |   |   |   |   |
| 4 | Total Contribution - Academic  | О |   |   |   |
| 5 | FY26 (7/1/25 – 6/30/26)  | 0 |   |   |   |
| 6 | FY27 (7/1/26 – 6/30/27)  | 0 |   |   |   |
| 7 | FY28 (7/1/27 – 6/30/28)  | 0 |   |   |   |
| 8 |  |   |   |   |   |
| 9 |  |   |   |   | , |

DO NOT MENTION THE PI BY NAME OR GENDER IN ANY UPLOADS.

25. Breakdown of Industry Partner(s) Expenditures: Please complete the Industry Partner Budget to show the detailed breakdown of expenditures for funds to be contributed by the Industry partner(s).

|  | А  | В      | С      | D | E |  |
|--|--|--------|--------|---|---|--|
| 1  | Inudstry Expenses for Project  |        |        |   |   |  |
| 2  | Category Options: Equipment, Supplies/Reagents, Renovation/Construction, Salaries, Indirects, Facility Costs |        |        |   |   |  |
| 3  |  |        |        |   |   |  |
| 4  | Total Contribution - Industry  | 0      |        |   |   |  |
| 5  | FY26 (7/1/25 – 6/30/26)  | 0      |        |   |   |  |
| 6  | FY27 (7/1/26 – 6/30/27)  | 0      |        |   |   |  |
| 7  | FY28 (7/1/27 – 6/30/28)  | 0      |        |   |   |  |
| 8  |  |        |        |   |   |  |
| 9  |  |        |        |   | • |  |
| 26. Upload letter(s) of commitment from each non-profit and Company partner outlining their financial and in-kind contributions (reagents, supplies, in-kind salary support, etc.) described in the budget form. Please have the letter reference your project title, but do not include applicant name/gender. If the non-profit applicant is not committing cost-share dollars, please include a letter from the institution describing their commitment to house the equipment and support the project in general. Reminder: At least one Company letter must include a commitment to pay the salary of at least one new postdoctoral scientist for the duration of the project. (required) |  |        |        |   |   |  |
|  |  | Choose | e File |   |   |  |
| Upload   | d a file. No files have been attached yet.   |        |        |   |   |  |

Acceptable file types: .pdf

DO NOT MENTION THE PI BY NAME OR GENDER IN ANY UPLOADS.

27. Is this a new project the team will be pursuing together, or a follow up to a previous research endeavor? Please describe. (required)

Limit: 75 words

Note: Sponsored Research Agreements (or other such similar arrangements) between parties that are executed before the application due date will not be considered as part of the letter of support for this program.

28. Supporting Data

|  | Choose File                |  | į                      |
|--|----------------------------|--|------------------------|
| Jpload a file. No files have been attached yet.  |                            |  | 1                      |
| Acceptable file types: .pdf  |                            |  |                        |
| Please upload a <b>.PDF</b> of any supporting data generated t<br>OR GENDER IN ANY UPLOADS.  | to date. Please limi       | this to <b>one</b> page. DO NOT MENTION THE PI BY NAME | ≣                      |
| Signature  |                            |  |                        |
| Blinded Declaration  |                            |  |                        |
| The MLSC is making a concerted effort to blind applicate mention the PI by name or gender unless specifically req  |                            | rs. As such we are requesting that you please do not   |                        |
| f there is mention of the PI's name or gender in the submove deemed ineligible. Prior to submission, please use CT (he/him/his or she/her/hers) in all text fields, references, only found in fields where specifically requested. | <b>TRL+F</b> to search the | e application for the PI's name and gendered pronoun   | -                      |
| Once you are ready to submit, please agree to the declar   | ration below by sel        | ecting the below checkbox.                             |                        |
| I agree that I have removed any mention except where explicitly asked. I understa application, except where explicitly requ  | and that if the I          | ars name or gender remains in the                      | (re<br>qui<br>red<br>) |
| Authorized Signature and Acceptance (require   | ed)                        |  | :                      |
|  | Choose File                |  | 1                      |
| Jpload a file. No files have been attached yet.  |                            |  | '                      |
| Acceptable file types: ndf_ing_ineg_nng  |                            |  |                        |

Please upload an image of the signature

Authorized Representative Signature and Acceptance -

I verify that I am authorized to commit my organization and to make this application on behalf of the organization. I certify that the above information is correct and that the statements made herein, including all attachments and exhibits, are true and correct to the best of my knowledge. The submission of false information to the Massachusetts Life Sciences Center (MLSC) is subject to prosecution under the False Claims Law at M.G.L. c. 12, sections 5A – 5O. I understand that this Novel Therapeutics Delivery Program Application may be disqualified if it does not contain all required information or if the Applicant does not meet the eligibility criteria required under the Program. I also acknowledge and agree that the MLSC has sole discretion to determine which applicants receive benefits under the Program. I specifically acknowledge that all of the terms and conditions of the Solicitation are mandatory. On behalf of the applicant, I understand and acknowledge that all materials submitted as part of this application may be subject to disclosure under the Massachusetts Public Records Law. "Public records" may not, however, include materials or data which fall within a specifically enumerated exemption set forth in the MLSC's enabling act, M.G.L. Chapter 23I. Such exemption may be applicable to materials or data submitted to the MLSC that consist of trade secrets or commercial or financial information regarding the operation of any business conducted by the company, or regarding the competitive position of such company in a particular field of endeavor (Trade Secrets Exemption). I understand and acknowledge that if I wish to submit materials or data to the MLSC that may be proprietary in nature and may fall within the parameters of the Trade Secrets Exemption, I must identify such materials and data as Confidential. I also understand that the receipt of such materials/data by the MLSC does not represent a finding that such materials/data do qualify for protection under the Trade Secrets Exemption.

| How did you near about the program? (required)  |  |  |  |  |
|---|--|--|--|--|
| Social Media  |  |  |  |  |
| MLSC Newsletter/Website   |  |  |  |  |
| Third Party (MassBio, MassMedic, etc.)  |  |  |  |  |
| Other (specify below)   |  |  |  |  |
| Select for the Principal Investigator to receive email notices and updates from MLSC  You may unsubscribe at any time.  |  |  |  |  |
| We look forward to reviewing your application and working together to develop new therapeutics and technologies to improve the lives of Massachusetts residents and support the Commonwealth as a leader in life sciences innovation. If you have any questions or need assistance, please contact our team at DrugDelivery@masslifesciences.com.  Save Draft Submit Form |  |  |  |  |

Drafts may be visible to the administrators of this program.